PacBio (PACB) announced that the Special Committee of its Board of Directors has concluded its independent investigation into previously disclosed allegations from an attorney representing an employee impacted by the recent reduction in force regarding certain employment practices and cybersecurity matters of the Company. The allegations did not involve the current, or any previously reported, financial results, and the investigation found no improper employment practices and no material inaccuracies or omissions with respect to the cybersecurity disclosures in the Company’s 2024 Form 10-K. Chairman of the Board John Milligan said, “We are pleased to have this investigation behind us and look forward to continuing to fulfill our mission of enabling the promise of genomics to better human health.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Pacific Biosciences: Strategic Shift to Long-Read Sequencing Fuels Buy Rating Amid Strong Q1 Performance
- Pacific Biosciences’ Earnings Call: Achievements and Challenges
- Pacific Biosciences’ Strategic Focus on Long-Read Sequencing and International Expansion Drives Growth Potential
- PacBio Reports Q1 2025 Financial Results Amid Restructuring
- Pac Bio options imply 14.4% move in share price post-earnings